Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05215574	TitleStudy of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2022-01-31	Location Arizona, United States California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs NGM831, NGM831 plus pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04708470	TitlePhase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer	Phase Phase 1, Phase 2	Date Added 2021-01-14	Location Maryland, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Bintrafusp alfa, Entinostat, NHS-IL12	Tags MSS/ MMRp
NCT ID NCT04362839	TitleRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2020-04-27	Location California, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy	Tags MSS/ MMRp
NCT ID NCT03796884	TitleLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer	Phase Phase 2	Date Added 2019-01-08	Location Pennsylvania, United States Washington, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Linaclotide	Tags MSS/ MMRp
NCT ID NCT03851614	TitleBasket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors	Phase Phase 2	Date Added 2019-02-22	Location Canada	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Cediranib, durvalumab, Olaparib	Tags MSS/ MMRp
NCT ID NCT03832855	TitleAssessing the Immunogenicity of pING-hHER3FL	Phase Phase 1	Date Added 2019-02-06	Location North Carolina, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs pING-hHER3FL	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04050709	TitleQUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers	Phase Phase 1	Date Added 2019-08-08	Location California, United States	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs PD-L1 t-haNK	Tags MSS/ MMRp
NCT ID NCT04607421	TitleA Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)	Phase Phase 3	Date Added 2020-10-29	Location Arizona, United States California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany India Italy Japan Korea, Republic of Mexico Netherlands New Zealand Norway Poland Russian Federation Slovakia South Africa Spain Sweden Taiwan Ukraine United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs 5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin	Tags MSS/ MMRp
NCT ID NCT03104439	TitleNivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer	Phase Phase 2	Date Added 2017-04-07	Location Massachusetts, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Ipilimumab, Nivolumab, Opdivo, Yervoy	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03785249	TitlePhase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1	Phase Phase 1, Phase 2	Date Added 2018-12-24	Location Alabama, United States Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Puerto Rico	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs afatinib, cetuximab, MRTX849, Pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 221 to 230 of 299 entries